European Hematology Association Congress (EHA)

The standard of care cohort comprised of patients across 3 global trials acted as a comparator for treatment with cilta-cel in patients with triple-class exposed multiple myeloma.

Further investigation will determine if initial results regarding the use of anakinra as prophylaxis for orvacabtagene autoleucel in multiple myeloma is efficacious enough for use in the real-world setting.

CancerNetwork® sat down with Ola Landgren, MD, PhD, at the 2021 EHA Congress to talk about his presentation on first-line standard of care for multiple myeloma.